Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | SMAD family member 2 | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target/s | Ortholog Group |
---|---|---|---|
Brugia malayi | MH2 domain containing protein | Get druggable targets OG5_131716 | All targets in OG5_131716 |
Loa Loa (eye worm) | transcription factor SMAD2 | Get druggable targets OG5_131716 | All targets in OG5_131716 |
Loa Loa (eye worm) | MH2 domain-containing protein | Get druggable targets OG5_131716 | All targets in OG5_131716 |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Brugia malayi | MH2 domain containing protein | SMAD family member 2 | 467 aa | 405 aa | 31.6 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trypanosoma cruzi | hypothetical protein, conserved | 0.0058 | 0.3143 | 0.5 |
Trypanosoma cruzi | mitochondrial RNA binding complex 1 subunit, putative | 0.0058 | 0.3143 | 0.5 |
Echinococcus multilocularis | zinc finger protein Ran binding | 0.0058 | 0.3143 | 0.3143 |
Echinococcus multilocularis | SWI:SNF matrix associated | 0.0163 | 1 | 1 |
Trypanosoma cruzi | Zn-finger in Ran binding protein and others, putative | 0.0058 | 0.3143 | 0.5 |
Schistosoma mansoni | RNA binding protein | 0.0058 | 0.3143 | 0.3143 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0163 | 1 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0058 | 0.3143 | 0.3143 |
Toxoplasma gondii | SWIB/MDM2 domain-containing protein | 0.0163 | 1 | 1 |
Trypanosoma cruzi | hypothetical protein, conserved | 0.0058 | 0.3143 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0058 | 0.3143 | 0.3143 |
Plasmodium vivax | hypothetical protein, conserved | 0.0163 | 1 | 0.5 |
Trypanosoma cruzi | WLM domain containing protein, putative | 0.0058 | 0.3143 | 0.5 |
Onchocerca volvulus | 0.0163 | 1 | 1 | |
Trypanosoma cruzi | hypothetical protein, conserved | 0.0058 | 0.3143 | 0.5 |
Toxoplasma gondii | DNA topoisomerase domain-containing protein | 0.0163 | 1 | 1 |
Trypanosoma brucei | Zn-finger in Ran binding protein and others/FYVE zinc finger, putative | 0.0058 | 0.3143 | 0.5 |
Plasmodium falciparum | SWIB/MDM2 domain-containing protein | 0.0163 | 1 | 1 |
Loa Loa (eye worm) | MH2 domain-containing protein | 0.0144 | 0.8786 | 0.8786 |
Loa Loa (eye worm) | transcription factor SMAD2 | 0.0144 | 0.8786 | 0.8786 |
Trypanosoma brucei | mitochondrial RNA binding complex 1 subunit | 0.0058 | 0.3143 | 0.5 |
Leishmania major | hypothetical protein, conserved | 0.0058 | 0.3143 | 0.5 |
Echinococcus granulosus | Zinc finger RanBP2 type | 0.0058 | 0.3143 | 0.3143 |
Trypanosoma cruzi | mitochondrial RNA binding complex 1 subunit, putative | 0.0058 | 0.3143 | 0.5 |
Loa Loa (eye worm) | SWIB/MDM2 domain-containing protein | 0.0163 | 1 | 1 |
Plasmodium vivax | SWIB/MDM2 domain-containing protein, putative | 0.0163 | 1 | 0.5 |
Echinococcus multilocularis | SWI:SNF matrix associated | 0.0163 | 1 | 1 |
Brugia malayi | SWIB/MDM2 domain containing protein | 0.0163 | 1 | 1 |
Echinococcus multilocularis | Zinc finger, RanBP2 type | 0.0058 | 0.3143 | 0.3143 |
Echinococcus granulosus | ring and YY1 binding protein | 0.0058 | 0.3143 | 0.3143 |
Brugia malayi | YY1-associated factor 2 | 0.0058 | 0.3143 | 0.3143 |
Loa Loa (eye worm) | hypothetical protein | 0.0058 | 0.3143 | 0.3143 |
Trypanosoma brucei | hypothetical protein, conserved | 0.0058 | 0.3143 | 0.5 |
Trypanosoma cruzi | Zn-finger in Ran binding protein and others/FYVE zinc finger, putative | 0.0058 | 0.3143 | 0.5 |
Leishmania major | hypothetical protein, conserved | 0.0058 | 0.3143 | 0.5 |
Echinococcus multilocularis | Upstream activation factor subunit UAF30 | 0.0163 | 1 | 1 |
Brugia malayi | Zn-finger in Ran binding protein and others containing protein | 0.0058 | 0.3143 | 0.3143 |
Brugia malayi | Zn-finger in Ran binding protein and others containing protein | 0.0058 | 0.3143 | 0.3143 |
Brugia malayi | Zn-finger in Ran binding protein and others containing protein | 0.0058 | 0.3143 | 0.3143 |
Schistosoma mansoni | hypothetical protein | 0.0058 | 0.3143 | 0.3143 |
Echinococcus granulosus | Upstream activation factor subunit UAF30 | 0.0163 | 1 | 1 |
Echinococcus multilocularis | ring and YY1 binding protein | 0.0058 | 0.3143 | 0.3143 |
Leishmania major | hypothetical protein, conserved | 0.0058 | 0.3143 | 0.5 |
Schistosoma mansoni | zinc finger protein | 0.0058 | 0.3143 | 0.3143 |
Plasmodium falciparum | SWIB/MDM2 domain-containing protein | 0.0163 | 1 | 1 |
Brugia malayi | brahma associated protein 60 kDa | 0.0163 | 1 | 1 |
Schistosoma mansoni | hypothetical protein | 0.0163 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0058 | 0.3143 | 0.3143 |
Leishmania major | hypothetical protein, conserved | 0.0058 | 0.3143 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0058 | 0.3143 | 0.3143 |
Schistosoma mansoni | brg-1 associated factor | 0.0163 | 1 | 1 |
Echinococcus multilocularis | Nuclear pore complex protein Nup153 | 0.0058 | 0.3143 | 0.3143 |
Schistosoma mansoni | fusion | 0.0058 | 0.3143 | 0.3143 |
Schistosoma mansoni | TRABID protein (C64 family) | 0.0058 | 0.3143 | 0.3143 |
Echinococcus granulosus | zinc finger protein Ran binding | 0.0058 | 0.3143 | 0.3143 |
Trypanosoma brucei | hypothetical protein, conserved | 0.0058 | 0.3143 | 0.5 |
Brugia malayi | Zn-finger in Ran binding protein and others containing protein | 0.0058 | 0.3143 | 0.3143 |
Schistosoma mansoni | hypothetical protein | 0.0163 | 1 | 1 |
Schistosoma mansoni | hypothetical protein | 0.0163 | 1 | 1 |
Echinococcus granulosus | SWI:SNF matrix associated | 0.0163 | 1 | 1 |
Chlamydia trachomatis | DNA topoisomerase I | 0.0163 | 1 | 0.5 |
Trypanosoma cruzi | WLM domain containing protein, putative | 0.0058 | 0.3143 | 0.5 |
Leishmania major | hypothetical protein, conserved | 0.0058 | 0.3143 | 0.5 |
Echinococcus multilocularis | SWI:SNF matrix associated | 0.0163 | 1 | 1 |
Loa Loa (eye worm) | brahma associated protein | 0.0163 | 1 | 1 |
Trypanosoma cruzi | Zn-finger in Ran binding protein and others, putative | 0.0058 | 0.3143 | 0.5 |
Chlamydia trachomatis | SWIB complex protein | 0.0163 | 1 | 0.5 |
Brugia malayi | MH2 domain containing protein | 0.0144 | 0.8786 | 0.8786 |
Echinococcus granulosus | Nuclear pore complex protein Nup153 | 0.0058 | 0.3143 | 0.3143 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 6.3096 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of TGF-b. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588856, AID588860] | ChEMBL. | No reference |
Potency (functional) | 26.8545 uM | PUBCHEM_BIOASSAY: qHTS profiling assay for firefly luciferase inhibitor/activator using purified enzyme and Km concentrations of substrates (counterscreen for miR-21 project). (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID2288, AID2289, AID2598, AID411] | ChEMBL. | No reference |
Potency (functional) | = 44.6684 um | PUBCHEM_BIOASSAY: qHTS Inhibitors of AmpC Beta-Lactamase (assay with detergent). (Class of assay: confirmatory) [Related pubchem assays: 1002 (Confirmation Concentration-Response Assay for Inhibitors of AmpC Beta-Lactamase (assay with detergent)), 585 (Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay without detergent) - a screen old NIH MLSMR collection), 584 (Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay with detergent) - a screen of the old NIH MLSMR collection), 1003 (Confirmation Cuvette-Based Assay for Inhibitors of AmpC Beta-Lactamase (assay with detergent))] | ChEMBL. | No reference |
Potency (functional) | 50.1187 uM | PubChem BioAssay. qHTS for Agonist of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS. (Class of assay: confirmatory) | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.